Mark Arthur Richards

Richards Mark Arthur

  • Professor, Department of Medicine
  • Consultant, Division of Cardiology, National University Heart Centre, Singapore, National University Health System
Administrative Appointment(s)
  • Director, Cardiovascular Research Institute, National University Health System
  • Lead, Cardiovascular Disease Summit Research Programme, National University Health System
Joint Appointment(s)
  • Director, Christchurch Heart Institute, University of Otago, New Zealand
Academic Qualifications
  • MBChB, University of Otago, New Zealand
  • MD (Dist), University of Otago, New Zealand
  • PhD, University of Otago, New Zealand
  • DSc, University of Otago, New Zealand
  • FRACP, Royal Australasian College of Physicians, Australasia
  • FRCP, Royal College of Physicians, United Kingdom
  • FRSNZ, Royal Society of New Zealand, New Zealand
Research Interest(s)
  • Biomarkers
  • Heart Failure
  • Coronary Heart Disease
  • Valvular Heart Disease
Recent Publications
  • 1. de Hoog VC, Lim SH, Bank IE, Gijsberts CM, Ibrahim IB, Kuan WS, Ooi SB, Chua T, den Ruijter HM, Pasterkamp G, Tai ES, Gao F, Doevendans PA, Wildbergh TX, Mosterd A, Richards AM, de Kleijn DP, Timmers L. 2015 Dec. Ethnic differences in clinical outcome of patients presenting to the emergency department with chest pain. European heart journal. Acute cardiovascular care. Eur Heart J Acute Cardiovasc Care . 10(7):e0131977. doi: 10.1177/2048872615623064. 26714971.
  • 2. Pickering JW, Young JM, George P, Aldous S, Cullen L, Greenslade JH, Richards AM, Troughton R, Ardagh M, Frampton CM, Than MP. 2015 Dec. The utility of presentation and 4-hour high sensitivity troponin I to rule-out acute myocardial infarction in the emergency department. Clin Biochem. 48(18):1219-24. doi: 10.1016/j.clinbiochem.2015.07.033. 26232285.
  • 3. Brunner-La Rocca HP, Eurlings L, Richards AM, Januzzi JL, Pfisterer ME, Dahlström U, Pinto YM, Karlström P, Erntell H, Berger R, Persson H, O'Connor CM, Moertl D, Gaggin HK, Frampton CM, Nicholls MG, Troughton RW. 2015 Dec. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. Eur J Heart Fail. 17(12):1252-61. doi: 10.1002/ejhf.401. 26419999.
  • 4. Liebetrau C, Gaede L, Dörr O, Blumenstein J, Rosenburg S, Hoffmann J, Troidl C, Hamm CW, Nef HM, Möllmann H, Richards AM, Pemberton CJ. 2015 Dec. Reference Values and Release Kinetics of B-Type Natriuretic Peptide Signal Peptide in Patients with Acute Myocardial Infarction. Clin Chem. 61(12):1532-9. doi: 10.1373/clinchem.2015.244327. 26506995.
  • 5. Richards AM. 2015 Dec. Plasma Neprilysin Concentrations: A New Prognostic Marker in Heart Failure?. Rev Esp Cardiol (Engl Ed). 68(12):1053-5. doi: 10.1016/j.rec.2015.09.004. 26547589.